Skip to main content

Rebound Weight Gain Common After Discontinuing Antiobesity Medications

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 25, 2025.

via HealthDay

FRIDAY, July 25, 2025 -- Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, according to a review published online July 21 in BMC Medicine.

Han Wu, from the Peking University People's Hospital in Beijing, and colleagues conducted a systematic review to explore the long-term effects of AOMs on body weight. The review included randomized controlled trials of AOMs conducted within populations for at least four weeks and followed for four or more weeks after discontinuation. Weight change was reported during drug treatment and after drug discontinuation.

The researchers found that compared with the control group, AOM treatment had weight loss effects at week 4 after discontinuation (weighted mean difference, −0.32 kg; 95 percent confidence interval, −3.60 to 2.7; P = 0.85). Compared with the control group, AOMs were associated with significant weight regain at eight weeks after drug discontinuation (weighted mean difference, 1.50 kg; 95 percent confidence interval, 1.32 to 1.68; P < 0.0001), a trend that continued through 12 and 20 weeks. Significant weight regain after 12 weeks of drug discontinuation was only seen in studies with glucagon-like peptide 1 receptor agonist-related drugs. Significant weight gain after drug discontinuation was seen in studies in which weight loss was greater during treatment than in the control group and in studies in which lifestyle interventions were continued.

"According to the trajectory of weight regain, body weight continued to decrease within four weeks after treatment discontinuation and then started to show a gradually increasing trend after eight weeks," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Opportunistic Community Screening IDs Uncontrolled Cardiovascular Risk Factors

FRIDAY, Aug. 15, 2025 -- Opportunistic pop-up community screening identifies a high prevalence of uncontrolled cardiovascular risk factors, according to a study published online...

Missed Opportunity Common in Patients With High-Grade Serous Ovarian Cancer

FRIDAY, Aug. 15, 2025 -- A considerable proportion of patients with high-grade serous cancer (HGSC) have missed opportunities for risk assessment with genetic testing and for...

EHR Notes Reveal Potential Racial Bias in Doctors' Perception of Patient Credibility

FRIDAY, Aug. 15, 2025 -- An analysis of more than 13 million electronic health record (EHR) notes shows potential racial bias in how doctors document patient trustworthiness...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.